Chronic Pharyngolaryngitis (Disorder)
Conditions
Brief summary
A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine formula in treating Chronic pharyngolaryngitis. Subjects will be randomized into a treatment group or placebo group for 8 weeks, and then followed by an 8-week post-treatment visit.
Detailed description
Chronic pharyngolaryngitis (CP), also known as chronic pharyngitis, is defined as the inflammation of the pharynx, which is at the back of the throat. CP is a common disease characterized by dry throat, sore throat, pharyngeal itching, dry cough, and difficulty in swallowing. In Western medicine, common treatment regimens for CP include lozenges, antibiotics, lasers, and cryotherapy. However, the above treatment modalities may not be effective, and the disease is likely to bounce back repeatedly. Chinese medicine has been used for the treatment of CP for a long time. Many studies have shown that treatment using Chinese herbal medicine is effective in relieving the symptoms of CP. This study is to evaluate the efficacy and safety of oral Qingyan Lihou Decoction in relieving the clinical symptoms of patients with CP.
Interventions
DRUGQingyan Lihou Decoction
Chinese medicine granules
OTHERPlacebo
Placebo granules
Sponsors
Chinese University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age or above (Chinese subjects only); * Persistent symptoms of pharyngitis (sore throat, globus, dry throat, dry cough, throat irritation) for more than 3 weeks; * Determined to be the following Chinese medicine syndromes by Registered Chinese Medicine Practitioners (RCMPs): Wind-heat invading the upper-jiao, or phlegm heat or Yin deficiency; * Visual analog scale (VAS) score for pain ≥ 50 mm; * Numeric rating scale (NRS) ≥ 6; and * Be able to give voluntary written informed consent.
Exclusion criteria
* Known severe medical conditions, such as cardiovascular, liver or renal dysfunction, diabetes mellitus, cancers, cerebrovascular diseases, blood system diseases; * Concomitant use of steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulants, and immunotherapy within the past week; * Impaired hematological profile and liver / renal function exceed the upper limit of the reference value by 2 times; * Known Allergic rhinitis; * Known Gastroesophageal Reflux Disease (GERD); * Known cancer or suspected cancer of throat/oesophagus; * Mechanical obstruction of the throat accountable for the symptoms; * Known alcohol and/or drug abuse; * Known allergic history to any Chinese herbal medicines; and * Subjects who are known pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The resolution rate of the clinical symptoms of CP | 8 weeks | Measure the resolution rate of the clinical symptoms at week 8. According to the "Guiding Principles for Clinical Research of Chinese Medicines", the degree of clinical symptom is divided into 4 grades: asymptomatic, mild symptom, moderate symptom, and severe symptom, with a score of 0\~3. |
| Improvement of laryngeal signs | 8 weeks | Observe the improvement of laryngeal signs via Flexible nasopharyngolaryngoscopy examination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete remission rate of Globus | 8 weeks | The rate of remission of the main clinical symptom Globus at week 8. According to the "Guiding Principles for Clinical Research of Chinese Medicines" \[16\], the degree of clinical symptom is divided into 4 grades: asymptomatic, mild symptom, moderate symptom, and severe symptom, with a score of 0\~3. |
| Complete remission rate of Globus symptom | 16 weeks | The rate of remission of main clinical symptom Globus at week 16. According to the "Guiding Principles for Clinical Research of Chinese Medicines" \[16\], the degree of clinical symptom is divided into 4 grades: asymptomatic, mild symptom, moderate symptom, and severe symptom, with a score of 0\~3. |
| Visual analogue scale (VAS) of Globus symptom | 8 weeks | Difficulty in swallowing is assessed using a VAS, which is 100 mm in length (100-mm VAS) anchored by two verbal descriptors, one for each extreme symptom (0 mm = not difficult, 100 mm = very difficult) |
| Change of Numeric rating scale of sore throat | 8 weeks | Intensity of sore throat will be assessed using an 11-point numeric rating scale (11-point NRS) with 0 representing one pain extreme (no pain) and 10 representing the other pain extreme (most severe pain) |
| Changes of serum level of cytokines | 8 weeks | Blood samples will be taken to detect the serum level of C reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete blood count (CBC), White blood cell (WBC), and Antinuclear antibody (ANA) using enzyme-linked immunosorbent assay (ELISA) kits. These are the markers for inflammatory response and severity. The higher the value, the more severity of the symptoms. |
| Changes of laryngeal hypersensitivity questionnaire (LHQ) | 8 weeks | LHQ contains 14 items with a 7-point Likert frequency response scale where 1 equates to all of the time and 7 equates to none of the time. 14 items will be divided into 3 categories, which is obstruction, pain and throat tickle. Average score of each category will be obtained and the total LHQ score will be the sum of those average scores. |
| Changes of oral microbiome | 8 weeks | The saliva sample will be collected from subjects, and it will be examined according to the protocol of the Microbiome Saliva DNA Kit. |
| Changes in Sore Throat Assessment Tool-10 (STAT-10) | 8 weeks | The STAT-10 is the first validated tool for measuring the intensity and duration of symptoms from the perspective of sore throat patients and for quantifying and comparing different treatment modalities in acute pharyngotonsillitis (APT) patients. STAT-10 contains 10-item questionnaire using a five-point Likert scale. The higher the score, the more severity of the symptoms. |
| Changes in Eating Assessment Tool-10 (EAT-10) | 8 weeks | It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem. The score is 0 to 40. The higher the score, the more severity of the swallowing difficulty. |
| Adverse event related to the study treatment | From baseline to week 16 | Any adverse event will be recorded during the study period, it will be graded by CTCAE. |
| Changes in 36-Item Short Form Survey Instrument (SF-36) | 8 weeks | It will be used to assess the patient's health status using 8 different dimensions including vitality, physical functioning, bodily pain, general health perceptions, role limitations due to physical health, role limitations due to emotional health, social role functioning and mental health. The possible score ranges from 0 to 100 points whereby 0 points represent the greatest possible limitation of health, while 100 points represent the absence of health restrictions. |
Countries
Hong Kong
Contacts
CONTACTCho Wing Lo
PRINCIPAL_INVESTIGATORZhixiu Lin
Hong Kong Institute of Integrative Medicine
Outcome results
None listed